The global market is expected to enjoy a valuation of US$ 123.2 Billion by the end of the year 2023, and further expand at a CAGR of 5.2% to reach a valuation of ~US$ 205.3 Billion by the year 2033. According to the recent study by Future Market Insights, degenerative diseases are leading the market with an expected share of about 31.7% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 117.6 Billion |
| Market Value 2023 | US$ 123.2 Billion |
| Market Value 2033 | US$ 205.3 Billion |
| CAGR 2023-2033 | 5.2% |
| Market Share of Top 5 Countries (2022) | 54.8% |
| Key Market Players List | Abbvie Inc, Alkermes Plc, Allergan Plc, AstraZeneca Plc, BIAL Group, Bristol-myers Squibb, Eisai Co, Ltd., Endo Pharmaceuticals, Eli Lilly and Co, and F. Hoffmann-La Roche Ltd. |
The CNS or central nervous system is the coordinating or control mechanism of the animal body, including humans. Degeneration of nervous tissues or disorders in the brain and spinal cords is the prominent reason for several types of neurodegenerative diseases.
New research activities conducted in the sphere of mental health and psychiatric disorders have increased the demand for treatment and therapeutic opportunities available in the CNS treatment and therapy market.
The growth of CNS therapeutics for the soaring cases of mental illness and central nervous system disorders associated with faulty lifestyle is providing the necessary impetus for the establishment and growth of the CNS treatment and therapy market across the geographical regions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for CNS treatment and therapy was around 57.8% of the overall ~US$ 203.6 Billion of the global antibody therapy market in 2022.
The sale of CNS treatment and therapy expanded at a CAGR of 4.66% from 2017 to 2022.
Over the years, increased incidents of psychological disorders and nervous breakdown have emerged as a major concern across the globe. By the applications of several types of chemical formulations such as anaesthetic anti-Parkinson's drugs and antiepileptic drugs, the CNS treatment and therapy has relieved many patients across the globe, creating a huge market.
According to Parkinson's Foundation, the global count of patients suffering from Parkinson's disease is estimated to be 10 million in 2022. The diagnosis report for other nervous system disorder diseases have also increased significantly in the recent past and is estimated to reach 82 million by 2030. This situation creates ample of opportunity for pharmaceutical companies to generate revenues by delivering treatment and therapeutic options for the patients.
Increased government funding to accelerate the clinical development of newly discovered drugs is expected to fuel the rapid growth of the central nervous system therapeutics market during the forecast period. The introduction of new therapies like serotonin and norepinephrine reuptake inhibitors (SNRIs) have acquired huge traction within a short period of time.
Thus, owing to the aforementioned factors, the global CNS treatment and therapy market is projected to expand at a CAGR of 5.2% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 3.99% |
| Jul-Dec (H2), 2021 (A) | 5.13% |
| Jan-Jun (H1),2022 Projected (P) | 3.70% |
| Jan-Jun (H1),2022 Outlook (O) | 4.00% |
| Jul-Dec (H2), 2022 Outlook (O) | 5.26% |
| Jul-Dec (H2), 2022 Projected (P) | 5.03% |
| Jan-Jun (H1), 2023 Projected (P) | 3.87% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 30↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 1↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 22↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 12↑ |
According to the Alzheimer’s Association, the number of patients suffering from Alzheimer’s is predicted to reach nearly 13 billion in the USA alone by 2050. Alzheimer’s, along with other neurological disorders in the ageing population, is predicted to keep demand for CNS treatment and therapy services high in the US market and other regions as well.
New product launches by adopting upgraded techniques are the prospective growth strategy that is adopted by major market players operating in the central nervous system therapeutics market. For instance, the Corbus Pharmaceutical Inc. of Japan started the commercialization of the Lenabasum drug in Japan by entering into an agreement with Kaken pharmaceutical company in 2019.
The rising cases of mental health disorders among the general population has provided the necessary impetus for the central and regional governments to make necessary provisions for the treatment of CNS disorders. Canada released its first national strategy for controlling dementia by spending US$ 200 Million though the Canadian Institute of Health Research in 2019.
The global CNS therapeutics is categorized based on the class of drugs used for the treatment of central nervous system disorders. Immunomodulators and interferon are analysed to be constantly driving the central nervous treatment drug market by the innovation of therapeutic molecules implemented for the treatment of neurological diseases symptoms.
Principal Consultant
Strong guidelines for the approval of newly developed drug Formulations before introduction into the market hamper the competitive edge of pharmaceutical companies investing heavily in research and development. Failure rates of various newly introduced drugs for nervous system therapeutics is also higher, which poses a major challenge for the growth of the market.
The wide availability of generic drugs is also anticipated to limit the growth of private market players supplying neurological disorder drugs, anaesthetics, anti-Parkinson drugs and its other variants. Agreement with government organizations to supply neurological disease prevention products can be established to incur higher profit from the CNS treatment and therapy services.
The introduction of novel drug delivery systems in the past decade have faced the issue of its acceptance in healthcare sectors of all regions.
Dissemination of proper information to the CNS treatment and therapy centres is the underlying challenge that may hinder the market players from realizing their full potential.
| Country | USA |
|---|---|
| 2023 | 31.70% |
| 2033 | 31.20% |
| BPS Analysis | -52 |
| Country | Germany |
|---|---|
| 2023 | 6.70% |
| 2033 | 7.20% |
| BPS Analysis | 46 |
| Country | UK |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | -3 |
| Country | Canada |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | 7 |
| Country | China |
|---|---|
| 2023 | 5.60% |
| 2033 | 6.20% |
| BPS Analysis | 59 |
The USA is set to hold a total market share of about 31.7% in 2023.
The primary causes of these enormous market growth tendencies in the USA market includes rising percentage of the elderly population and the greatest level of healthcare spending. The demand within the global market is projected to rise as people become more aware of the neurodegenerative illnesses, autoimmune and inflammatory disorders, and their potential for treatment.
Germany is set to hold a market share of nearly 6.7% in the global CNS treatment and therapy market in 2023.
Given the intricacy of the condition and the scarcity of accessible controlled research, among the most sensitive issues in neuro-oncology is the treatment of primary CNS lymphoma. The European Association of Neuro-Oncology established a multidisciplinary task force in 2013 to develop evidence-based recommendations for immunocompetent adults with primary CNS lymphoma.
The recommendations cover topics such as the management of aged patients as well as features of care for surgery, systemic and intrathecal chemotherapy, intense chemotherapy with autologous stem-cell transplantation, radiation, and ophthalmic symptoms. The recommendations should support doctors in their day-to-day work and decision-making, act as a foundation for next neuro-oncology studies, and increase market value in Germany.
China contributes about 5.6% revenue share to the global market.
China has become a significant market for anesthetics anti-Parkinson medications as a result of modernizing its healthcare infrastructure. With the increasing development and manufacturing of novel biologics for CNS treatment, the market is set to advance, as Chinese manufacturing firms take more outsourcing activities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Biologics are set to hold a share of around 68.7% in the global market, in 2023.
The blood brain barrier (BBB), which hinders attaining enough drug concentrations at sites of action, precludes many central nervous system (CNS) illnesses from being properly treated by systemically delivered medicines. Direct CNS delivery will probably play a bigger part in therapy as a result of the rising prevalence of neurodegenerative illnesses and the inability of most systemically delivered medicines to penetrate the blood-brain barrier.
This problem is solved by administering big chemicals, cells, viral vectors, oligonucleotides, and other innovative therapeutics directly to the CNS through the subarachnoid space, ventricular system, or parenchyma.
Antidepressant segment holds about one-third value share within the global market.
CNS depressants are prescribed to treat seizures, anxiety, panic attacks, and sleeplessness. They can also be administered before surgery to calm nerves and relax. Sedatives, tranquillizers, and hypnotics are medications that depress the central nervous system (CNS). These medications can reduce brain activity, making them effective for treating anxiety, panic attacks, severe stress reactions, and sleep difficulties.
Degenerative diseases are set to hold a share of around 31.7% in the global market, in 2023.
Millions of people worldwide are affected by neurodegenerative disorders. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease. According to an estimate from the Alzheimer's Disease Association, 6.2 million people in the USA had Alzheimer's disease by 2022.
Hospital pharmacies segment is set to hold a share of around 48.6% in the global market, in 2023.
Increasing prevalence of neurodegenerative disorders, as well as the rising patient inflow into hospital settings are factors propelling institutional sales within the hospital pharmacies. With appropriate prescription and treatment regime, this segment is set to expand over the forecast period, owed to greater patient compliance, as well as availability of medications in-house.
The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel research activities in the field of nervous system disorder diseases.
Global players with higher valuation incur higher spending on clinical trials of different products such as anesthetic anti-Parkinson drugs for launching it in market. Strategic collaborations is the major strategy adopted by such market players to expand their consumer base.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the CNS treatment and therapy space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Drug, Drug Class, Disease, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is estimated to acquire US$ 123.2 billion in 2023.
Nonselective, multipotent therapies appear to be more effective, thus propelling market growth.
The United States accounts for 31% of the market in 2023.
Germany holds a market share of nearly 6.7% in the market in 2023.
The scarcity of accessible controlled research, among the most sensitive issues is driving growth.
1. Market- Executive Summary | CNS Treatment and Therapy Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusion 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Product USPs 4.3. Promotional Strategies, By Key Players 4.4. Regulatory Scenario 4.5. Technology Assessment 4.6. PESTEL Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Industry Market Outlook 5.1.3. Global Antibody Therapy Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Advancements in Drug Discovery Techniques 5.2.2. Rising Awareness on Neuropsychiatric Disorders 5.2.3. Increasing Research and Development Activities on Psychedelic Use for Mental Health 5.2.4. Rising Number of Neuroscience Drug Manufacturers 5.2.5. Rising Incidence of Psychiatric Disorders 5.2.6. Introduction of Novel Drug Delivery Systems 5.2.7. Increasing Initiatives by Government 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Drug 6.1.2. Revenue By Drug Class 6.1.3. Revenue By Disease 6.1.4. Revenue By Distribution Channel 6.1.5. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033 8.3.1. Biologics 8.3.2. Non Biologics 8.4. Market Attractiveness Analysis By Drug 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 9.3.1. Antidepressant 9.3.2. Analgesics 9.3.3. Immunomodulators 9.3.4. Interferons 9.3.5. Decarboxylase Inhibitors 9.3.6. Others 9.4. Market Attractiveness Analysis By Drug Class 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Disease, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease, 2023 to 2033 10.3.1. Neurovascular Disease 10.3.2. Degenerative Disease 10.3.3. Infectious Disease 10.3.4. Mental Health 10.3.5. Others 10.4. Market Attractiveness Analysis By Disease 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Online Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East & Africa(MEA) 12.4. Market Attractiveness Analysis by Region 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. US 13.3.1.2. Canada 13.3.2. By Drug 13.3.3. By Drug Class 13.3.4. By Disease 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug 13.4.3. By Drug Class 13.4.4. By Disease 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. USA Market 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug 13.8.1.2.2. By Drug Class 13.8.1.2.3. By Disease 13.8.1.2.4. By Distribution Channel 13.8.2. Canada Market 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug 13.8.2.2.2. By Drug Class 13.8.2.2.3. By Disease 13.8.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug 14.3.3. By Drug Class 14.3.4. By Disease 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug 14.4.3. By Drug Class 14.4.4. By Disease 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Brazil Market 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug 14.8.1.2.2. By Drug Class 14.8.1.2.3. By Disease 14.8.1.2.4. By Distribution Channel 14.8.2. Mexico Market 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug 14.8.2.2.2. By Drug Class 14.8.2.2.3. By Disease 14.8.2.2.4. By Distribution Channel 14.8.3. Argentina Market 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug 14.8.3.2.2. By Drug Class 14.8.3.2.3. By Disease 14.8.3.2.4. By Distribution Channel 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Drug 15.3.3. By Drug Class 15.3.4. By Disease 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug 15.4.3. By Drug Class 15.4.4. By Disease 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug 15.8.1.2.2. By Drug Class 15.8.1.2.3. By Disease 15.8.1.2.4. By Distribution Channel 15.8.2. Italy Market 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug 15.8.2.2.2. By Drug Class 15.8.2.2.3. By Disease 15.8.2.2.4. By Distribution Channel 15.8.3. France Market 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug 15.8.3.2.2. By Drug Class 15.8.3.2.3. By Disease 15.8.3.2.4. By Distribution Channel 15.8.4. United Kingdom Market 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Drug 15.8.4.2.2. By Drug Class 15.8.4.2.3. By Disease 15.8.4.2.4. By Distribution Channel 15.8.5. Spain Market 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Drug 15.8.5.2.2. By Drug Class 15.8.5.2.3. By Disease 15.8.5.2.4. By Distribution Channel 15.8.6. BENELUX Market 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Drug 15.8.6.2.2. By Drug Class 15.8.6.2.3. By Disease 15.8.6.2.4. By Distribution Channel 15.8.7. Russia Market 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Drug 15.8.7.2.2. By Drug Class 15.8.7.2.3. By Disease 15.8.7.2.4. By Distribution Channel 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Drug 16.3.3. By Drug Class 16.3.4. By Disease 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug 16.4.3. By Drug Class 16.4.4. By Disease 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug 16.8.1.2.2. By Drug Class 16.8.1.2.3. By Disease 16.8.1.2.4. By Distribution Channel 16.8.2. Thailand Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug 16.8.2.2.2. By Drug Class 16.8.2.2.3. By Disease 16.8.2.2.4. By Distribution Channel 16.8.3. Indonesia Market 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug 16.8.3.2.2. By Drug Class 16.8.3.2.3. By Disease 16.8.3.2.4. By Distribution Channel 16.8.4. Malaysia Market 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Drug 16.8.4.2.2. By Drug Class 16.8.4.2.3. By Disease 16.8.4.2.4. By Distribution Channel 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug 17.4.3. By Drug Class 17.4.4. By Disease 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. China Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug 17.8.1.2.2. By Drug Class 17.8.1.2.3. By Disease 17.8.1.2.4. By Distribution Channel 17.8.2. Japan Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug 17.8.2.2.2. By Drug Class 17.8.2.2.3. By Disease 17.8.2.2.4. By Distribution Channel 17.8.3. South Korea Market 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Drug 17.8.3.2.2. By Drug Class 17.8.3.2.3. By Disease 17.8.3.2.4. By Distribution Channel 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug 18.3.3. By Drug Class 18.3.4. By Disease 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug 18.4.3. By Drug Class 18.4.4. By Disease 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug 18.8.1.2.2. By Drug Class 18.8.1.2.3. By Disease 18.8.1.2.4. By Distribution Channel 18.8.2. New Zealand Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug 18.8.2.2.2. By Drug Class 18.8.2.2.3. By Disease 18.8.2.2.4. By Distribution Channel 19. Middle East and Africa Market Analysis 2017 to 2022and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Drug 19.3.3. By Drug Class 19.3.4. By Disease 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug 19.4.3. By Drug Class 19.4.4. By Disease 19.4.5. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Drug 19.8.1.2.2. By Drug Class 19.8.1.2.3. By Disease 19.8.1.2.4. By Distribution Channel 19.8.2. Türkiye Market 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Drug 19.8.2.2.2. By Drug Class 19.8.2.2.3. By Disease 19.8.2.2.4. By Distribution Channel 19.8.3. South Africa Market 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Drug 19.8.3.2.2. By Drug Class 19.8.3.2.3. By Disease 19.8.3.2.4. By Distribution Channel 19.8.4. North Africa Market 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Drug 19.8.4.2.2. By Drug Class 19.8.4.2.3. By Disease 19.8.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. Regional footprint of Players 20.4.2. Product footprint of Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Deep Dive 21.2.1. AbbVie Inc. 21.2.1.1. Overview 21.2.1.2. Key Financials 21.2.1.3. Sales Footprint 21.2.1.4. SWOT Analysis 21.2.1.5. Strategy Overview 21.2.1.5.1. Marketing Strategy 21.2.1.5.2. Product Strategy 21.2.1.5.3. Channel Strategy 21.2.2. Alkermes Plc 21.2.2.1. Overview 21.2.2.2. Key Financials 21.2.2.3. Sales Footprint 21.2.2.4. SWOT Analysis 21.2.2.5. Strategy Overview 21.2.2.5.1. Marketing Strategy 21.2.2.5.2. Product Strategy 21.2.2.5.3. Channel Strategy 21.2.3. Allergan Plc 21.2.3.1. Overview 21.2.3.2. Key Financials 21.2.3.3. Sales Footprint 21.2.3.4. SWOT Analysis 21.2.3.5. Strategy Overview 21.2.3.5.1. Marketing Strategy 21.2.3.5.2. Product Strategy 21.2.3.5.3. Channel Strategy 21.2.4. AstraZeneca Plc 21.2.4.1. Overview 21.2.4.2. Key Financials 21.2.4.3. Sales Footprint 21.2.4.4. SWOT Analysis 21.2.4.5. Strategy Overview 21.2.4.5.1. Marketing Strategy 21.2.4.5.2. Product Strategy 21.2.4.5.3. Channel Strategy 21.2.5. BIAL Group 21.2.5.1. Overview 21.2.5.2. Key Financials 21.2.5.3. Sales Footprint 21.2.5.4. SWOT Analysis 21.2.5.5. Strategy Overview 21.2.5.5.1. Marketing Strategy 21.2.5.5.2. Product Strategy 21.2.5.5.3. Channel Strategy 21.2.6. Bristol-myers Squibb 21.2.6.1. Overview 21.2.6.2. Key Financials 21.2.6.3. Sales Footprint 21.2.6.4. SWOT Analysis 21.2.6.5. Strategy Overview 21.2.6.5.1. Marketing Strategy 21.2.6.5.2. Product Strategy 21.2.6.5.3. Channel Strategy 21.2.7. Eisai Co, Ltd. 21.2.7.1. Overview 21.2.7.2. Key Financials 21.2.7.3. Sales Footprint 21.2.7.4. SWOT Analysis 21.2.7.5. Strategy Overview 21.2.7.5.1. Marketing Strategy 21.2.7.5.2. Product Strategy 21.2.7.5.3. Channel Strategy 21.2.8. Endo Pharmaceuticals 21.2.8.1. Overview 21.2.8.2. Key Financials 21.2.8.3. Sales Footprint 21.2.8.4. SWOT Analysis 21.2.8.5. Strategy Overview 21.2.8.5.1. Marketing Strategy 21.2.8.5.2. Product Strategy 21.2.8.5.3. Channel Strategy 21.2.9. Eli Lilly and Co 21.2.9.1. Overview 21.2.9.2. Key Financials 21.2.9.3. Sales Footprint 21.2.9.4. SWOT Analysis 21.2.9.5. Strategy Overview 21.2.9.5.1. Marketing Strategy 21.2.9.5.2. Product Strategy 21.2.9.5.3. Channel Strategy 21.2.10. F. Hoffmann-La Roche Ltd. 21.2.10.1. Overview 21.2.10.2. Key Financials 21.2.10.3. Sales Footprint 21.2.10.4. SWOT Analysis 21.2.10.5. Strategy Overview 21.2.10.5.1. Marketing Strategy 21.2.10.5.2. Product Strategy 21.2.10.5.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
CNS Treatment and Therapy Market
